Cover
Cover | Mar. 25, 2022 |
Cover [Abstract] | |
Document Type | 8-K/A |
Amendment Flag | true |
Amendment Description | Allarity Therapeutics, Inc. (the “Company”) is filing this Amendment No. 1 on Form 8-K/A (“Amendment”) to the Company’s Current Report on Form 8-K with a date of report of March 25, 2022 (“Form 8-K”), as filed with the Securities and Exchange Commission on March 31, 2022 (“Original Filing Date”) to supplement its disclosure under Item 4.02 (a) and to add Exhibit 99.1. This Amendment should be read in conjunction with the Form 8-K. This Amendment speaks as of the Original Filing Date, does not reflect events that may have occurred subsequent to the Original Filing Date, and does not modify or update any disclosure made in the Form 8-K unless otherwise amended in this Amendment. |
Document Period End Date | Mar. 25, 2022 |
Entity File Number | 001-41160 |
Entity Registrant Name | ALLARITY THERAPEUTICS, INC. |
Entity Central Index Key | 0001860657 |
Entity Tax Identification Number | 87-2147982 |
Entity Incorporation, State or Country Code | DE |
Entity Address, Address Line One | 210 Broadway |
Entity Address, Address Line Two | Suite 201 |
Entity Address, City or Town | Cambridge |
Entity Address, State or Province | MA |
Entity Address, Postal Zip Code | 02139 |
City Area Code | 401 |
Local Phone Number | 426-4664 |
Written Communications | false |
Soliciting Material | false |
Pre-commencement Tender Offer | false |
Pre-commencement Issuer Tender Offer | false |
Title of 12(b) Security | Common Stock, par value $0.0001 per share |
Trading Symbol | ALLR |
Security Exchange Name | NASDAQ |
Entity Emerging Growth Company | true |
Elected Not To Use the Extended Transition Period | false |